Carbon Reduction Plan

Supplier name: Aventis Pharma Limited

Publication Date: 24/05/2024

Commitment to achieving Net Zero

Aventis Pharma Limited is committed to achieving Net Zero emissions by 2045.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases (GHGs) that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 01/01//2019 – 31/12/2019 (Financial Year 2019)

Additional Details relating to the Baseline Emissions calculations

The baseline exercise was carried out for the first time for the year 2019. The baseline has been restated compared to the Carbon Reduction Plan published by Aventis Pharma Limited in 2023 for the year 2022. The restatement of the figures is due a change in methodology in which the global parent company's (Sanofi's) carbon footprint is used to pro-rata for the UK using volumes of medicines that are purchased and sold. Despite using the global parent company data, this CRP reflects the footprint and commitments of Aventis Pharma Limited; the bidding entity, in the UK. In future years when the data collection improves, Aventis Pharma Limited will restate the baseline value if changes result from improvements in data or the methodology used. The carbon footprint also extends beyond the scope of the PPN 06/21 regulations as all relevant Scope 3 categories have been included.

Baseline year emissions:

EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	4,567
Scope 2	2,283
Scope 3*	50,234
Total Emissions	57,085

^{*}Included sources for Scope 3 emissions are as follows: purchase of goods and services, capital goods, fuel and energy related activities (FERA), upstream transportation and distribution of goods, waste, business travel, employee commuting, downstream transportation and distribution

of goods, processing of sold products, use of sold products, end-of-life treatment and investments).

Current Emissions Reporting

As per the baseline year, the below figures for 2023, 2022, and 2021 have been restated, in line with the change in methodology stated above.

EMISSIONS	Reporting Year				
	Current Year:	Previous Year:	Previous Year:		
	01/01/2023 - 31/12/2023	01/01/2022 - 31/12/2022	01/01/2021 - 31/12/2021		
	(Financial Year 2023)	(Financial Year 2022)	(Financial Year 2021)		
Scope 1	2,592	2,967	3,261		
Scope 2 (Location- based)	648	1,116	1,630		
Scope 3*	29,160	33,111	35,868		
Total emissions	32,400	37,203	40,760		


^{*}Included sources for Scope 3 emissions are as follows: purchase of goods and services, capital goods, fuel and energy related activities (FERA), upstream transportation and distribution of goods, waste, business travel, employee commuting, downstream transportation and distribution of goods, processing of sold products, use of sold products, end-of-life treatment and investments).

Emissions Reduction targets

Aventis Pharma Limited has set a target to achieve Net Zero by 2045.

If Aventis Pharma Limited's emissions reduce in line with our Net Zero ambition, we would need to realise a reduction of 3,857.5 tCO $_2$ e (12%) over the next 5 years (by 2028) when compared to 2023 emissions. The below graph shows that when mapping the Net Zero trajectory required from the 2019 baseline, Aventis Pharma Limited are currently on track to meet Net Zero by 2045.

Progress against our 2045 Net Zero commitment will be tracked annually, and the graph below will be updated.



Carbon Reduction Projects

At the parent company level, the following initiatives have been completed or actioned which also has a positive impact on the bidding entity:

- 86% of waste was reused or recovered in 2022. By 2025, 100% of sites will be landfill free, with >90% of waste reused, recycled or recovered.
- Water stewardship and efficiency plans implemented on all sites by 2023.
 Between 2019 and 2022, water withdrawals reduced by 13%.
- Purchase 100% renewable energy across global operations by 2030.
- Foster an eco-fleet (100% of fleet will contain fully electric vehicles) by 2030. Currently, 34% of the car fleet is an eco-fleet.
- Reduce GHG emissions from activities by 55% from 2019 to 2030.

- Monitor, manage and reduce emissions on 100% of manufacturing sites by 2025. Specific programs have been engaged on 72% of manufacturing sites and on 100% of priority sites.
- Eco-design approach for all new products by 2025 and top selling products by 2030.
- Review of long-distance transportation such as using Sea instead of air and using rail instead of air/road.
- Removal of plastic from our vaccine product packaging

Aventis Pharma Limited have actioned or have completed the following carbon reduction projects since the baseline year of 2019 to support the reduction required to meet net zero by 2045:

- Procuring 100% renewable electricity at the UK Reading Head Office.
- All office, meeting rooms, communal area and LED car park lighting are controlled by PIR sensors and non-occupancy timers to minimise energy wastage in un-occupied areas.
- Recommissioning the Building Management System (BMS)
- Transition of our car fleet towards carbon neutrality by 2030 and as part of this, the company car scheme aims to be fully electric in the next 3 years, for every electric car leased our supplier plant a tree and we have installed 30 additional Battery Electric Vehicle chargers onsite at Reading.
- Achieved ISO 14001 Environmental Management certification in 2023.
- Food waste is tracked in order to reduce food wastage.
- Sponsorship of restoration projects with GreenTheUK, including oyster restoration project and Wildflower Planting
- We grow our own vegetables and herbs on our local rooftop ensuring fresh organic produce within our restaurant.
- We have reduced our food deliveries and consolidated our deliveries into fewer weekly drop offs by using a local supplier.
- Our kitchen is committed to only using red meat in 20% of our menus.
- If any trees need to be cut back or down due to disease, we chip the trees and use the chipping as mulch. The chippings rot down then enrich the soil and help plants to grow.
- We have changed our Fruit supplier to "Fruitful Office", they will plant a fruit tree for every basket they deliver.
- Aventis Pharma Limited have reduced commuting with reduced commuting days per week for employees, adopting the cycle to work scheme and installing electric bike chargers in the bike store and electric shuttles to work.
- Logistics suppliers closing down smaller depots and building a state-ofthe-art distribution centre with both initiatives resulting in lower carbon emissions.

Future Carbon Reduction Initiatives

- Install 68.25kWp Solar Photovoltaic (PV) panels at the Reading office.
- Global / UK Procurement led initiatives are underway to partner with Sanofi Suppliers on Environment, Social and Governance (ESG) maturation and decarbonisation of our processes.
- Reduce food waste by 50% by 2026.
- We plan to decarbonise our supply chain by engaging with key suppliers and encourage them to decarbonise and set emissions reduction targets aligned with our own targets.
- Develop and operate a global program by 2030 to promote responsible use and the proper disposal of unused medicines, medical devices and packaging. Including, organising and setting up a pilot "Insulin Pen Recycling Scheme".

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

	••
Date:22 nd May 2024	

Signed on behalf of the supplier: